Hutchmed China Ltd - Company Profile
Powered by
All the data and insights you need on Hutchmed China Ltd in one report.
- Save hours of research time and resources with
our up-to-date Hutchmed China Ltd Strategy Report
- Understand Hutchmed China Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Hutchmed China Catalyst Calendar
Proactively evaluate Hutchmed China Ltd’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Hutchmed China Catalyst Calendar data
Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
---|---|---|---|---|---|---|---|
31 Dec 2019 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
31 Dec 2019 | Phase II Trial Results | Hutchison MediPharma Ltd | - | fruquintinib | Oncology | Non-Small Cell Lung Cancer | Company SEC Filings |
31 Dec 2019 | Phase III Trial Results | Hutchison MediPharma Ltd | - | surufatinib | Oncology | Neuroendocrine Tumors | Company Press Release |
12 Dec 2019 | Phase II Trial Initiation | Hutchison MediPharma Ltd; Hutchison Whampoa Pharmaceutical Shanghai Co Ltd | - | surufatinib | Oncology | Adenocarcinoma Of The Gastroesophageal Junction; Bile Duct Cancer (Cholangiocarcinoma) ; Endometrial Cancer; Esophageal Cancer; Esophageal Squamous Cell Carcinoma (ESCC); Gastric Cancer; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Small-Cell Lung Cancer; Soft Tissue Sarcoma; Solid Tumor; Thyroid Cancer | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer